MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
75.69
+1.18
+1.58%
After Hours: 75.69 0 0.00% 18:56 12/16 EST
OPEN
73.49
PREV CLOSE
74.51
HIGH
76.51
LOW
72.73
VOLUME
2.22M
TURNOVER
--
52 WEEK HIGH
76.51
52 WEEK LOW
25.34
MARKET CAP
14.59B
P/E (TTM)
-18.0782
1D
5D
1M
3M
1Y
5Y
1D
BridgeBio Oncology Therapeutics to Present at J.P. Morgan Healthcare Conference
Reuters · 8h ago
BridgeBio Pharma Is Maintained at Outperform by Leerink Partners
Dow Jones · 1d ago
BridgeBio Pharma Price Target Raised to $86.00/Share From $75.00 by Leerink Partners
Dow Jones · 1d ago
Leerink Partners Maintains Outperform on BridgeBio Pharma, Raises Price Target to $86
Benzinga · 1d ago
Is the Market Bullish or Bearish on BridgeBio Pharma Inc?
Benzinga · 1d ago
Leerink Partners Remains a Buy on BridgeBio Pharma (BBIO)
TipRanks · 1d ago
Ionis Pharmaceuticals price target raised to $100 from $85 at Leerink
TipRanks · 1d ago
Alnylam price target lowered to $351 from $370 at Leerink
TipRanks · 1d ago
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.